09:25 AM EDT, 08/18/2025 (MT Newswires) -- Capricor Therapeutics ( CAPR ) said Monday the first subjects have been dosed in a phase 1 trial evaluating its StealthX exosome-based vaccine.

The study is funded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases under the US Department of Health and Human Services' Project NextGen, Capricor said.

Initial data from the study is expected in Q1 2026, according to a statement.